Generation of β cell-specific human cytotoxic T cells by lentiviral transduction and their survival in immunodeficient human leucocyte antigen-transgenic mice

J. Babad, G. Mukherjee, A. Follenzi, Riyasat Ali, B. O. Roep, L. D. Shultz, P. Santamaria, O. O. Yang, Harris Goldstein, D. L. Greiner, Teresa P. DiLorenzo

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Several β cell antigens recognized by T cells in the non-obese diabetic (NOD) mouse model of type 1 diabetes (T1D) are also T cell targets in the human disease. While numerous antigen-specific therapies prevent diabetes in NOD mice, successful translation of rodent findings to patients has been difficult. A human leucocyte antigen (HLA)-transgenic mouse model incorporating human β cell-specific T cells might provide a better platform for evaluating antigen-specific therapies. The ability to study such T cells is limited by their low frequency in peripheral blood and the difficulty in obtaining islet-infiltrating T cells from patients. We have worked to overcome this limitation by using lentiviral transduction to 'reprogram' primary human CD8 T cells to express three T cell receptors (TCRs) specific for a peptide derived from the β cell antigen islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP265-273) and recognized in the context of the human class I major histocompatibility complex (MHC) molecule HLA-A2. The TCRs bound peptide/MHC multimers with a range of avidities, but all bound with at least 10-fold lower avidity than the anti-viral TCR used for comparison. One exhibited antigenic recognition promiscuity. The β cell-specific human CD8 T cells generated by lentiviral transduction with one of the TCRs released interferon (IFN)-γ in response to antigen and exhibited cytotoxic activity against peptide-pulsed target cells. The cells engrafted in HLA-A2-transgenic NOD-scid IL2rγnull mice and could be detected in the blood, spleen and pancreas up to 5weeks post-transfer, suggesting the utility of this approach for the evaluation of T cell-modulatory therapies for T1D and other T cell-mediated autoimmune diseases.

Original languageEnglish (US)
Pages (from-to)398-413
Number of pages16
JournalClinical and Experimental Immunology
Volume179
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

HLA Antigens
Transgenic Mice
T-Lymphocytes
Survival
T-Cell Antigen Receptor
Antigens
Inbred NOD Mouse
Major Histocompatibility Complex
Type 1 Diabetes Mellitus
varespladib methyl
Peptides
Glucose-6-Phosphatase
Cell- and Tissue-Based Therapy
Islets of Langerhans
Interferons
Autoimmune Diseases
Pancreas
Rodentia
Catalytic Domain
Spleen

Keywords

  • Autoimmunity
  • CD8 T cells
  • Type 1 diabetes

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Generation of β cell-specific human cytotoxic T cells by lentiviral transduction and their survival in immunodeficient human leucocyte antigen-transgenic mice. / Babad, J.; Mukherjee, G.; Follenzi, A.; Ali, Riyasat; Roep, B. O.; Shultz, L. D.; Santamaria, P.; Yang, O. O.; Goldstein, Harris; Greiner, D. L.; DiLorenzo, Teresa P.

In: Clinical and Experimental Immunology, Vol. 179, No. 3, 01.03.2015, p. 398-413.

Research output: Contribution to journalArticle

Babad, J. ; Mukherjee, G. ; Follenzi, A. ; Ali, Riyasat ; Roep, B. O. ; Shultz, L. D. ; Santamaria, P. ; Yang, O. O. ; Goldstein, Harris ; Greiner, D. L. ; DiLorenzo, Teresa P. / Generation of β cell-specific human cytotoxic T cells by lentiviral transduction and their survival in immunodeficient human leucocyte antigen-transgenic mice. In: Clinical and Experimental Immunology. 2015 ; Vol. 179, No. 3. pp. 398-413.
@article{39a65c43ef6e4f46b1fb7a91a6a610cf,
title = "Generation of β cell-specific human cytotoxic T cells by lentiviral transduction and their survival in immunodeficient human leucocyte antigen-transgenic mice",
abstract = "Several β cell antigens recognized by T cells in the non-obese diabetic (NOD) mouse model of type 1 diabetes (T1D) are also T cell targets in the human disease. While numerous antigen-specific therapies prevent diabetes in NOD mice, successful translation of rodent findings to patients has been difficult. A human leucocyte antigen (HLA)-transgenic mouse model incorporating human β cell-specific T cells might provide a better platform for evaluating antigen-specific therapies. The ability to study such T cells is limited by their low frequency in peripheral blood and the difficulty in obtaining islet-infiltrating T cells from patients. We have worked to overcome this limitation by using lentiviral transduction to 'reprogram' primary human CD8 T cells to express three T cell receptors (TCRs) specific for a peptide derived from the β cell antigen islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP265-273) and recognized in the context of the human class I major histocompatibility complex (MHC) molecule HLA-A2. The TCRs bound peptide/MHC multimers with a range of avidities, but all bound with at least 10-fold lower avidity than the anti-viral TCR used for comparison. One exhibited antigenic recognition promiscuity. The β cell-specific human CD8 T cells generated by lentiviral transduction with one of the TCRs released interferon (IFN)-γ in response to antigen and exhibited cytotoxic activity against peptide-pulsed target cells. The cells engrafted in HLA-A2-transgenic NOD-scid IL2rγnull mice and could be detected in the blood, spleen and pancreas up to 5weeks post-transfer, suggesting the utility of this approach for the evaluation of T cell-modulatory therapies for T1D and other T cell-mediated autoimmune diseases.",
keywords = "Autoimmunity, CD8 T cells, Type 1 diabetes",
author = "J. Babad and G. Mukherjee and A. Follenzi and Riyasat Ali and Roep, {B. O.} and Shultz, {L. D.} and P. Santamaria and Yang, {O. O.} and Harris Goldstein and Greiner, {D. L.} and DiLorenzo, {Teresa P.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1111/cei.12465",
language = "English (US)",
volume = "179",
pages = "398--413",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Generation of β cell-specific human cytotoxic T cells by lentiviral transduction and their survival in immunodeficient human leucocyte antigen-transgenic mice

AU - Babad, J.

AU - Mukherjee, G.

AU - Follenzi, A.

AU - Ali, Riyasat

AU - Roep, B. O.

AU - Shultz, L. D.

AU - Santamaria, P.

AU - Yang, O. O.

AU - Goldstein, Harris

AU - Greiner, D. L.

AU - DiLorenzo, Teresa P.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Several β cell antigens recognized by T cells in the non-obese diabetic (NOD) mouse model of type 1 diabetes (T1D) are also T cell targets in the human disease. While numerous antigen-specific therapies prevent diabetes in NOD mice, successful translation of rodent findings to patients has been difficult. A human leucocyte antigen (HLA)-transgenic mouse model incorporating human β cell-specific T cells might provide a better platform for evaluating antigen-specific therapies. The ability to study such T cells is limited by their low frequency in peripheral blood and the difficulty in obtaining islet-infiltrating T cells from patients. We have worked to overcome this limitation by using lentiviral transduction to 'reprogram' primary human CD8 T cells to express three T cell receptors (TCRs) specific for a peptide derived from the β cell antigen islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP265-273) and recognized in the context of the human class I major histocompatibility complex (MHC) molecule HLA-A2. The TCRs bound peptide/MHC multimers with a range of avidities, but all bound with at least 10-fold lower avidity than the anti-viral TCR used for comparison. One exhibited antigenic recognition promiscuity. The β cell-specific human CD8 T cells generated by lentiviral transduction with one of the TCRs released interferon (IFN)-γ in response to antigen and exhibited cytotoxic activity against peptide-pulsed target cells. The cells engrafted in HLA-A2-transgenic NOD-scid IL2rγnull mice and could be detected in the blood, spleen and pancreas up to 5weeks post-transfer, suggesting the utility of this approach for the evaluation of T cell-modulatory therapies for T1D and other T cell-mediated autoimmune diseases.

AB - Several β cell antigens recognized by T cells in the non-obese diabetic (NOD) mouse model of type 1 diabetes (T1D) are also T cell targets in the human disease. While numerous antigen-specific therapies prevent diabetes in NOD mice, successful translation of rodent findings to patients has been difficult. A human leucocyte antigen (HLA)-transgenic mouse model incorporating human β cell-specific T cells might provide a better platform for evaluating antigen-specific therapies. The ability to study such T cells is limited by their low frequency in peripheral blood and the difficulty in obtaining islet-infiltrating T cells from patients. We have worked to overcome this limitation by using lentiviral transduction to 'reprogram' primary human CD8 T cells to express three T cell receptors (TCRs) specific for a peptide derived from the β cell antigen islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP265-273) and recognized in the context of the human class I major histocompatibility complex (MHC) molecule HLA-A2. The TCRs bound peptide/MHC multimers with a range of avidities, but all bound with at least 10-fold lower avidity than the anti-viral TCR used for comparison. One exhibited antigenic recognition promiscuity. The β cell-specific human CD8 T cells generated by lentiviral transduction with one of the TCRs released interferon (IFN)-γ in response to antigen and exhibited cytotoxic activity against peptide-pulsed target cells. The cells engrafted in HLA-A2-transgenic NOD-scid IL2rγnull mice and could be detected in the blood, spleen and pancreas up to 5weeks post-transfer, suggesting the utility of this approach for the evaluation of T cell-modulatory therapies for T1D and other T cell-mediated autoimmune diseases.

KW - Autoimmunity

KW - CD8 T cells

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84922789087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922789087&partnerID=8YFLogxK

U2 - 10.1111/cei.12465

DO - 10.1111/cei.12465

M3 - Article

C2 - 25302633

AN - SCOPUS:84922789087

VL - 179

SP - 398

EP - 413

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 3

ER -